Industry
Biotechnology
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 1:56 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 1:48 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 9:18 am
Portfolio Pulse from Vaishali Prayag
August 16, 2024 | 6:59 pm
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 6:58 pm
Portfolio Pulse from Avi Kapoor
August 16, 2024 | 6:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 4:43 pm
Portfolio Pulse from Avi Kapoor
August 16, 2024 | 4:20 pm
Portfolio Pulse from Chris Katje
August 16, 2024 | 3:40 pm
Portfolio Pulse from Avi Kapoor
August 16, 2024 | 1:56 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.